Outlook Therapeutics, Inc. (OTLK) Stock Forecast & Price Prediction 2024, 2025, 2030, 2040, and 2050
Get detailed Outlook Therapeutics, Inc. (OTLK) stock forecast for 2024, monthly, along with long-term OTLK price prediction from 2025 to 2050. Look at historical stock performance, analyst recommendations (Buy, Sell, or Hold), and the latest Outlook Therapeutics, Inc. headlines.
1 Month Prediction
$13.19 [491.53%]
3 Month Prediction
$9.36 [319.52%]
6 Month Prediction
$3.81 [70.66%]
1 Year Prediction
$1.00 [-55.16%]
3 Year Prediction
$1.00 [-55.16%]
5 Year Prediction
$1.00 [-55.16%]
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., established in 2010 and based in Iselin, New Jersey, is a biopharmaceutical company that develops ophthalmic formulations for retinal diseases. Their primary focus is on ONS-5010/LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab that treats conditions like wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Outlook Therapeutics, Inc. (OTLK) Historical Performance
IPO Date
Outlook Therapeutics, Inc. (NASDAQ:OTLK) went public on 13 May, 2016.
Change
Since inception, OTLK has decreased by 99.57%. In the last 5 years, OTLK has fallen from $15.20 to $2.23, a massive -85.33% decrease since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $55.20 and a low of $1.89.
52 Week Range
$0.87
$12.85
The current price $2.23 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
OTLK Stock Price History
Based on OTLK stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the OTLK stock has fallen from $12.02 - $27.2 to $2.23 - $2.23, which is down -95.95%. Currently, the stock follows downward trend.
Here, we have calculated stock range of OTLK, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $12.02 - $27.2 | $18.82 | -65.85 | 1 Year Change |
| 2021 | $18.7 - $55.2 | $41.73 | -24.28 | 2 Year Change |
| 2022 | $20.4 - $35.6 | $25.5 | -53.73 | 3 Year Change |
| 2023 | $4.42 - $34.8 | $18.79 | -65.9 | 4 Year Change |
| 2024 | $1.89 - $11.94 | $6.83 | -87.61 | 5 Year Change |
| 2025 | $2.23 - $2.23 | $2.23 | -95.95 | 6 Year Change |
OTLK Price Performance
6-Month Performance
OTLK stock dropped by 69.66% in the last six months.
1-Year Performance
The stock has trended downwards by 74.49% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 93.16%.
5-Year Performance
In the last 5 years, the stock has gone down by 85.33%.
According to Outlook Therapeutics, Inc.'s historical data, below graph gives us the exact picture of how the OTLK stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 2 years and a decline in 3 years.
2020
120.34% ↑
2021
4.62% ↑
2022
20.59% ↓
2023
63.52% ↓
2024
76.02% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Outlook Therapeutics, Inc. (OTLK) Financials & Stock Analysis
Market Capitalization
Outlook Therapeutics, Inc. has a market capitalization of $55.54M, which places OTLK in the micro-cap category.
Fundamental Analysis
EPS: $nan (Q3), $-4.06 (1Y)
EPS decreased nan% since last quarter, and decreased 13.98% since last year.
Net Income: $5.69 M (Q3), $-75.37 M (1Y)
Net Income decreased 87.18% since last quarter, and increased 27.78% since last year.
Free Cash Flow: $-16.98 M (Q3), $-68.79 M (1Y)
Free Cash Flow decreased N/A since last quarter, and increased N/A since last year.
Below, we have listed 12 key indicators for Fundamental analysis for OTLK stock. These indicators help you understand Outlook Therapeutics, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for OTLK stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $1.96 |
| SMA50 | $3.07 |
| SMA200 | $6.21 |
| RSI | 64.32 |
| Beta | 0.63 |
SMA20 < Current Price
This signals OTLK stock is in short-term bullish momentum.
SMA50 > Current Price
This signals OTLK stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals OTLK stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for OTLK stock is Neutral. Out of all indicators, 2 indicates bullish signals, 3 signals bearish trends and 4 gives neutral trends. The OTLK stock forecast was last updated on 18 January, 2025.
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to fall to $1.00 by the end of 2025, and can reach around $21.46 to $1.08 in 2026. And, the long-term forecast suggests that the stock may further drop to $1.37 - $1.28 in 2028, and $1.67 - $0.45 by 2031. So, the OTLK stock shows a strong downward trend in the next several years.
Short-term OTLK Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-02 | $13.19 | 491.48% |
| 2025-03 | $14.26 | 539.46% |
| 2025-04 | $9.36 | 319.73% |
| 2025-05 | $5.99 | 168.61% |
| 2025-06 | $4.87 | 118.39% |
| 2025-07 | $3.81 | 70.85% |
| 2025-08 | $1.00 | -55.16% |
| 2025-09 | $1.00 | -55.16% |
| 2025-10 | $1.00 | -55.16% |
| 2025-11 | $1.00 | -55.16% |
| 2025-12 | $1.00 | -55.16% |
In 2025, the OTLK stock price is expected to fluctuate between $1.0 and $14.26. According to the monthly forecast, the stock could drop to $1.00 by December 2024. If compared to the OTLK's current price, the stock could lose -55.16% by the end of this year.
Long-term OTLK Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $21.46 | $1.62 | $1.08 | -51.57% |
| 2027 | $0.74 | $1.67 | $0.77 | -65.47% |
| 2028 | $1.37 | $0.77 | $1.28 | -42.6% |
| 2029 | $1.05 | $1.08 | $0.98 | -56.05% |
| 2030 | $0.63 | $0.97 | $1.04 | -53.36% |
| 2031 | $1.67 | $0.33 | $0.45 | -79.82% |
| 2032 | $1.50 | $0.90 | $1.55 | -30.49% |
| 2033 | $1.78 | $1.14 | $1.61 | -27.8% |
| 2034 | $0.36 | $0.84 | $0.59 | -73.54% |
| 2035 | $0.80 | $1.14 | $0.07 | -96.86% |
| 2036 | $0.63 | $1.19 | $1.61 | -27.8% |
| 2037 | $1.56 | $0.97 | $0.95 | -57.4% |
| 2038 | $0.43 | $1.83 | $0.10 | -95.52% |
| 2039 | $1.30 | $0.93 | $1.04 | -53.36% |
| 2040 | $1.40 | $-0.01 | $0.99 | -55.61% |
| 2041 | $0.77 | $0.76 | $2.21 | -0.9% |
| 2042 | $0.65 | $0.97 | $1.42 | -36.32% |
| 2043 | $0.04 | $1.11 | $1.93 | -13.45% |
| 2044 | $0.63 | $0.82 | $1.01 | -54.71% |
| 2045 | $1.08 | $1.16 | $1.41 | -36.77% |
| 2046 | $1.20 | $0.67 | $0.79 | -64.57% |
| 2047 | $1.04 | $1.42 | $0.55 | -75.34% |
| 2048 | $0.90 | $0.63 | $1.17 | -47.53% |
| 2049 | $0.92 | $1.61 | $1.12 | -49.78% |
| 2050 | $0.69 | $0.51 | $0.72 | -67.71% |
| 2051 | $0.83 | $1.06 | $0.48 | -78.48% |
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction & Forecast 2025
At the start of 2025, the OTLK stock was at $2.23. Today, it is trading at $2.23, which is 0.00% increase from price at the beginning of the year. By the end of this year, you can expect the stock to fall to $1.00 by December 2025 with a -55.16% change.
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the OTLK stock. During this period, the OTLK's price is forecasted to shift from $21.46 to $1.04, which is -95.15% loss.
In 2026, the stock would possibly open at $21.46, descends to $1.62 by mid-year, and wraps up at $1.08, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $0.63, drop to $0.97 by mid-year, and finish at $1.04, which is -53.36% change from current price.
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $1.67 to $0.99, which is down -79.78%
In 2031, we can expect OTLK to fluctuate between $0.45 and $1.67, a shift indicating a -79.78% loss by year-end compared to current price. And Until 2040, OTLK can likely vary from $0.99 to $1.40. By the end of 2040, the stock could record a -55.73% fall from today's stock price.
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the OTLK stock can see an a downturn from $0.77 to $0.72 in this period. In 2041, the stock can experience a low of $0.76 by mid-year, closing the year at $2.21. This results in a -66.04% decrease from today.
Moving towards the end of 2050, OTLK is projected to open the year at $0.69. The stock may dip to $0.51 during mid-year and finish the year at $0.72. Compared to the stock's current price, this translates to an overall loss of -67.60% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
OTLK Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | - | $0.38 | 16.09% ▲ | $161.03 ▲ |
| OCGN | Ocugen, Inc. | - | $0.78 | -3.11% ▼ | $275.15 ▲ |
| MRNA | Moderna, Inc. | - | $42.25 | 1.61% ▲ | $304.87 ▲ |
| IPA | ImmunoPrecise Antibodies Ltd. | - | $0.53 | 28.28% ▲ | $117.56 ▲ |
| NVAX | Novavax, Inc. | - | $9.31 | 15.86% ▲ | $74.57 ▲ |
Last updated Jan 18 at 7 AM
OTLK : Buy, Sell Or Hold?
Analyst Ratings
Based on 4 analysts, 0 rated as a strong buy, 3 recommended a buy, 1 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.Three months ago, out of 5 analysts, 0 analysts gave a strong buy rating, 5 a buy rating, 0 a hold rating, 0 advised selling, and 0 suggested a strong sell.So, according to analyst ratings, the recommendation for OTLK stock is Buy.Expert Analysis
According to OTLK short-term and long-term forecast, Outlook Therapeutics, Inc. shares are projected to go down by 67.71%, and reach a value of $0.72 per share by 2050.
As per technical analysis, indicators show a Neutral sentiment, while Fear & Greed Index stands at 42.857142857142854, which signals Fear. Also, OTLK has recorded 12/30 green days, which reflects a 60.0% positivity rate with a price volatility of 0.07%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that OTLK stock is undervalued. So, Based on OTLK prediction and analysis, it may be the best time to hold OTLK stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "OTLK” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.